Jonathan Boyd is the associate director of the Musculoskeletal Laboratory and an associate professor of orthopaedics at the West Virginia University School of Medicine (WVUSOM). He holds additional joint appointments in the Department of Physiology and Pharmacology (WVUSOM) and the Department of Occupational and Environmental Health Sciences (WVU School of Public Health). Dr. Boyd also holds appointments as a guest professor at Fulda University (Germany) and a guest researcher at the Centers for Disease Control and Prevention at the National Institute for Occupational Safety and Health (CDC/NIOSH). He received his BS Biochemistry from the University of Texas at Austin in 1998 and his PhD Environmental Toxicology from Texas Tech University in 2004. His expertise is in mechanistic toxicology, mammalian signal transduction, and musculoskeletal trauma. Dr. Boyd's research uses fundamental thermodynamic principles to investigate the pharmacodynamic responses of living systems. In general, he is interested in understanding the mammalian response to both chemical and physical stressors, and specifically, he is working toward an understanding of how humans integrate (from cellular mechanisms to physiological integration) chemical and biochemical signals in response to stimuli. His research involves multiple hierarchical levels of biological samples that include mammalian cell culture, animal models, and human subjects coupled with analytical techniques that range from single‐point detectors to multidimensional imaging. The applications of his work range from toxicity screening to surgical diagnostics, and he has published over 40 papers, technical reports, and book chapters associated with his research. Finally, Jonathan is married to the love of his life, Naomi, and together they have the three best children on Earth, Jack, Lucy, and Gwen, who all fill his life with pure joy.

Richard (Rick) Neubig is professor and chair of Pharmacology & Toxicology at Michigan State University associated with the three medical colleges. Dr. Neubig received his BS in Chemistry from the University of Michigan in 1975, his MD from Harvard Medical School in the Harvard‐MIT Program in Health Sciences and Technology in 1981, and his PhD in Pharmacology from Harvard University in 1981. He trained in internal medicine at the University of Michigan Hospitals and then joined the faculty in the Departments of Pharmacology and Internal Medicine in 1984. He moved to Michigan State University in 2013 to take the position of chair of Pharmacology & Toxicology. His research has primarily focused on G‐protein‐coupled receptor (GPCR) signaling. His early work in the 1980s and 1990s primarily used ligand binding kinetics and biochemical studies to decipher receptor/G‐protein interactions. In the mid‐1990s his work took a turn to translational research and academic drug discovery. He helped establish high‐throughput screening and drug discovery centers at both the University of Michigan and Michigan State University. His current work relates to therapeutic discovery in cancer, scleroderma, and other fibrotic diseases as well as mechanisms and therapeutics of genetic epilepsies. He was president of the American Society for Pharmacology and Experimental Therapeutics (ASPET) (2012–2015), and he received the Astellas and ASPET‐Pharmacia awards for translational pharmacology from that organization. He served on the IUPHAR Receptor Nomenclature Committee from 2000 to 2015 and was GPCR co‐chair. He was named Fellow of the American Association for the Advancement of Science (AAAS) in 2015 and is currently chair of Section S, Pharmaceutical Sciences, of the AAAS. He loves nature and the outdoors, a passion that he shares with his amazing wife, Laura Liebler. They are the lucky parents of two wonderful children, Graham and Maia, who have brought them equally wonderful spouses and a totally awesome granddaughter, Enna.